On January 1, 2025, a 2.8% cut to Medicare physician reimbursement went into effect. The cut followed a 1.68% cut from 2024, while the cost of running a medical practice continues to rise due to ...

The Association for Clinical Oncology (ASCO) has signed on to a joint letter to Congressional leaders about the impact of potential Medicaid cuts on access to cancer care for children. Led by the ...

The Conquer Cancer Patient Advocate Award Program helps patient advocates attend ASCO Meetings to learn of important advances in their areas of interest. As of July 2024, more than 1,150 patient ...

To continue, please click on one of the buttons below or access other content through the navigation menu or search.

The Association for Clinical Oncology (ASCO) is one of nearly 50 specialty groups urging the National Institutes of Health (NIH) to rescind a recent policy change limiting how much research ...

Thank you for your interest in the ASCO Plenary Series. Effective June 2024, the Series will pause indefinitely and is not accepting abstract submissions. With greatly increased demand for in-person ...

ASCO is committed to promoting prevention science and integrating evidence-based prevention strategies into oncology practice. ASCO’s prevention goals are to promote clinical, behavioral, and ...

BOLERO-4: Multicenter, open-label, phase II study of everolimus plus letrozole as first-line therapy in ER + HER2-metastatic breast cancer.

The American Society of Clinical Oncology (ASCO) has launched a new policy development process. Stakeholders can now submit new health policy topic ideas or suggested updates to existing ASCO policy ...

Longitudinal MRI-based fusion novel model to predict pathological complete response in breast cancer treated with neoadjuvant chemotherapy: A multicenter, retrospective study.

Prostate-specific antigen value at 3 & 7 months (PSA-3mo, PSA-7mo) and overall survival (OS) in metastatic hormone-sensitive prostate cancer (mHSPC) treated with androgen deprivation (ADT) with or ...

Radioparp: A phase I of olaparib with radiation therapy (RT) in patients with inflammatory, locoregionally advanced or metastatic triple-negative breast cancer (TNBC) or patient with operated TNBC ...